EvolveImmune Therapeutics to Present New Preclinical Data Highlighting Pipeline Progress for EVOLVE T Cell Engager Platform at 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
23 oct. 2024 07h00 HE
|
EvolveImmune
Multiple Presentations on Lead Development Candidate EVOLVE104 to Showcase Preclinical Safety and Efficacy Profile and Precision Therapeutic Strategy as Company Advances Program Toward Clinic for...
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
21 oct. 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
ICPO Foundation geht eine Partnerschaft mit der International Atomic Energy Agency (IAEA) ein
10 oct. 2024 04h15 HE
|
ICPO Foundation
Die Parteien kooperieren weltweit im Bereich der therapeutischen klinischen Anwendungen der Nuklearmedizin in der Onkologie. 10. Oktober 2024 – Wiesbaden, Deutschland. Heute kündigte die...
ICPO Foundation partners with the International Atomic Energy Agency (IAEA)
10 oct. 2024 04h15 HE
|
ICPO Foundation
The parties cooperate in the area of therapeutic clinical applications of nuclear medicine in oncology worldwide. October 10, 2024 – Wiesbaden, Germany. Today, the International Centers for...
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
12 août 2024 16h05 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and
Provides Business Update
Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024
02 juil. 2024 08h30 HE
|
Biodexa Pharmaceuticals PLC
July 2, 2024 Biodexa Pharmaceuticals PLC Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 After Only Two Infusions and Two...
Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
05 juin 2024 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress
08 mai 2024 16h02 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
25 avr. 2024 09h00 HE
|
INmune Bio, Inc.
Boca Raton, Florida, April 25, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the...
[Latest] Global Lung Tumor Market Size/Share Worth USD 46.3 Billion by 2033 at a 7.7% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
15 avr. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, April 15, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lung Tumor Market Size, Trends and Insights By Product (Imaging systems, Biopsy...